2022 Bipolar disorder Sleep and mental health 
Psychiatric Times
JULY 1, 2025
SHOW MORE The FDA will update ADHD medication labels, warning of weight loss risks in children under 6, urging careful monitoring by health care professionals. Healthcare professionals should monitor weight and growth in young patients on these medications and consider alternative treatments if adverse effects occur.
Psychiatric Times
JUNE 27, 2025
Ms Barbee has a passion to reduce the stigma around mental health and promoting increased access to mental health care and education of both clinicians and the general public. She has also served as advisory board participant for Supernus Pharmaceuticals and Axsome Therapeutics. Subscribe Now!
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Psychiatric Times
JUNE 23, 2025
The COMP005 trial is the first phase 3 study of synthetic psilocybin, marking a milestone in psychedelic research for mental health. No unexpected safety issues or imbalance in suicidal ideation were observed between treatment and placebo groups. points (95% CI [-5.7, -1.5]) in change at the primary endpoint.
Psychiatric Times
JUNE 13, 2025
of patients who were prescribed antipsychotics for their psychiatric illness and had evidence of tardive dyskinesia (TD) had TD recorded properly in their electronic health records, supporting the idea that TD is often underreported and misdiagnosed and, therefore, not treated appropriately.
Psychiatric Times
JUNE 12, 2025
link] Related Videos Related Content Advertisement May 29th 2025 Treatment Comparison: Somnolence/Sedation With Dopamine Partial Agonists vs D2 Receptor Antagonists Leah Kuntz April 9th 2022 Here's to a Psychedelic Revolution Amir Inamdar MBBS, DNB (Psych), MFPM May 23rd 2025 Looking Ahead to the ASCP Annual Meeting With Joseph F.
Psychiatric Times
JULY 2, 2025
FDA Indications, Potential Future Indications, and Areas of Investigation for GLP-1 RAs Soon after their introduction, GLP-1 RAs’ significant weight-lowering effects and health benefits in other medical disorders became apparent, with relatively greater metabolic and weight loss benefits reported with newer GLP-1 RAs and dual agonists.
Mad in America
JULY 10, 2025
W hen I first saw Laura Delano’s story was being published by Penguin, a major publisher, I knew that we were on the brink of change by way of the public narrative around mental health in the west. Like Laura, I was diagnosed with bipolar disorder at age seventeen.
Expert insights. Personalized for you.
98 
Let's personalize your content